3 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 3, Recruiting 3, Active not recruiting 1, Terminated 1 |
Follow amrubicin: new trials by email Literature Review of amrubicin trials Research Report on amrubicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer ABBV-706, Topotecan, Lurbinectedin - Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 531 | 2026-07-02 | 2026-09-23 |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only) - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 3 | Recruiting | Gilead Sciences | 695 | 2025-04-04 | 2026-10-20 |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer Ifinatamab deruxtecan, Topotecan, Amrubicin - Small Cell Lung Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 540 | 2024-05-21 | 2026-08-06 |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer Tarlatamab, Lurbinectedin, Topotecan - Small Cell Lung Cancer (SCLC) | Phase 3 | Active not recruiting | Amgen | 509 | 2023-05-31 | 2026-01-05 |
| Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer Nivolumab, Topotecan, Amrubicin - Lung Cancer | Phase 3 | Completed | Bristol-Myers Squibb | 569 | 2015-09-14 | 2023-07-27 |
| Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Amrubicin Hydrochloride, Etoposide-Cisplatin combined chemotherapy - Lung Cancer | Phase 3 | Completed | Marubeni Pharmaceuticals (Suzhou) Co., Ltd. | 300 | 2008-04-01 | 2014-07-18 |
| AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy Amrubicin, Topotecan - Small Cell Lung Cancer | Phase 3 | Completed | Celgene | 637 | 2007-09-01 | 2019-11-06 |
| Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC) Amrubicin Hydrochloride - Small-cell Lung Cancer | Phase 3 | Terminated | Sumitomo Pharma Co., Ltd. | 130 | 2006-04-01 | 2022-04-12 |
Small Cell Lung Carcinoma (5) · Lung Neoplasms (3) · Neoplasms (1)
AbbVie (1) · Amgen (1) · Bristol-Myers Squibb (1) · Celgene (1) · Daiichi Sankyo (1) · Gilead Sciences (1) · Marubeni Pharmaceuticals (Suzhou) Co., Ltd. (1) · Sumitomo Pharma Co., Ltd. (1)
Belgium (6) · France (6) · Germany (6) · Japan (6) · Spain (6) · United States (6) · Australia (5) · Austria (5) · Brazil (5) · China (5) · Greece (5) · Hungary (5) · Italy (5) · Poland (5) · Switzerland (5)
Drug Development Division (1) · Markus Renschler, M.D. (1) · Yan Sun, MD (1)
PMID 27061082, PMID 39530627, PMID 41055143, PMID 42377743
2015 (1), 2023 (1), 2025 (1)